A little-known biotech running low on cash looks to get its own $100M IPO from pandemic market
It’s been heady for biotechs breaking into a pandemic stock market: $233 million for ADC Therapeutics, $165 million for Zentalis, and $120 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
